Data Governance Key In Maximizing Value Of Electronic Health Information
As of 5 April, 2021, health care providers, health IT developers and health information exchanges in the US face penalties for blocking the free exchange of electronic health information, including patient requests for health records. But strong data governance policies are needed to make health information serve patient needs, according to a Prix Galien panel of experts.
You may also be interested in...
Through a grant from the National Cancer Institute (NCI), Charles River Analytics is building a platform to collect and analyze biometric sensor data and connected devices used by cancer patients across the US. The goal of the project is to support large-scale population health research and to improve cancer outcomes.
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.